Lakefront Biotherapeutics (GLPGF) Net Income towards Common Stockholders Growth (5y) (2019 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Income towards Common Stockholders Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.32% |
| Mar 31, 2026 | 7.66% |
| Dec 31, 2025 | 345.16% |
| Sep 30, 2025 | -25.10% |
| Jun 30, 2025 | 27.66% |
| Mar 31, 2025 | -23.63% |
| Dec 31, 2024 | 261.91% |
| Sep 30, 2024 | -17.76% |
| Jun 30, 2024 | 25.22% |
| Mar 31, 2024 | 30.41% |
| Dec 31, 2023 | 568.39% |
| Sep 30, 2023 | -32.25% |
| Jun 30, 2023 | 15.15% |
| Mar 31, 2023 | 20.53% |
| Dec 31, 2022 | 53.93% |
| Sep 30, 2022 | 20.16% |
| Jun 30, 2022 | 12.32% |
| Mar 31, 2022 | -0.60% |
| Dec 31, 2021 | -24.18% |
| Jun 30, 2021 | -79.10% |